ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2815

Pathological Roles By Siglec and Type I Interferons for the Development of Autoimmune Congenital Heart Block

Robert M. Clancy1, Marc Halushka2 and Jill P. Buyon1, 1NYU School of Medicine, New York, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, Biomarkers, fibrosis and interferons, Macrophage

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Given that diseases associated with anti-SSA/Ro such as SLE and Sjögren’s syndrome associate with an upregulation of type I interferons, recent attention has focused on a potential role for IFN in the pathogenesis of congenital heart block (CHB). Based on the consistent demonstration of macrophages and multinucleated giant cells in areas of injury, it is relevant that Sialic Acid Binding Ig Like Lectin 1 (SIGLEC1), a receptor on monocytes/macrophages, is upregulated by IFN. Functionally, Siglec-1 expressing macrophages might play an important role as effector cells in fibrosis. Accordingly, this study leveraged both autopsy tissue and freshly isolated macrophages from a fetal heart dying with CHB to address whether IFN-α contributes to the pathogenesis of CHB by regulating activated macrophages in affected cardiac tissue.

Methods: Three approaches were taken to evaluate Siglec-1 expression. Transcriptomic analysis was performed on macrophages freshly isolated from a fetal heart dying with CHB at 19 weeks and a heart from an otherwise healthy electively terminated fetus using (DAPI negative cells with isolation by flow using antibodies to CD45). Immunohistochemistry was performed on another fetal heart dying with CHB. In vitro experiments utilized cultured healthy human macrophages transfected with anti-SSA/Ro- associated ssRNA as a proxy for the in vivo conditions.

Results: Transcriptomes of the two hearts for each isolated leukocyte fraction were compared. By following 213 IFN inducible genes, there was enrichment of targeted transcripts in CHB vs control (p=0.0001) and SIGLEC1, which was 200-fold more abundant in CHB vs control and ranked among the top three differentially expressed candidates. In another fetal heart dying with CHB, Siglec1 staining as detected by antibody HPA053457 was prominent in areas of injury. By morphology, the two cell types expressing Siglec 1 were macrophages and dendritic cells. In vitro experiments were performed in accordance with previous laboratory work, in which a model of anti-SSA/Ro-associated injury exploits macrophages stimulated with the ssRNA component (hY3) of the SSA/Ro immune complex. IFN inducible genes (15 transcripts) were among the 30 most highly upregulated genes in hY3 stimulated conditions and SIGLEC1 was two-fold more abundant in CHB vs control. Given the enrichment of type I IFN-responsive genes in the macrophage transcriptome, a WISH cell line was selected to evaluate supernatants from macrophages transfected with hY3. IFIT1, MX1, and EIF2AK2 transcripts were significantly increased in the WISH cells treated with hY3 macrophage supernatants, but not macrophage supernatants alone (N = 7, P =0.02).

Conclusion: These data now provide a link between IFN and the inflammatory and possibly fibrosing component of CHB and position Siglec-1 positive macrophages as integral to the process.


Disclosure: R. M. Clancy, None; M. Halushka, None; J. P. Buyon, None.

To cite this abstract in AMA style:

Clancy RM, Halushka M, Buyon JP. Pathological Roles By Siglec and Type I Interferons for the Development of Autoimmune Congenital Heart Block [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pathological-roles-by-siglec-and-type-i-interferons-for-the-development-of-autoimmune-congenital-heart-block/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathological-roles-by-siglec-and-type-i-interferons-for-the-development-of-autoimmune-congenital-heart-block/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology